Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis?

Rev Esp Med Nucl Imagen Mol. Mar-Apr 2016;35(2):102-6. doi: 10.1016/j.remn.2015.09.002. Epub 2015 Oct 27.

Abstract

Objective: In this study, an evaluation was made of the relationship between the serum levels of carcinoembryonic antigen (CEA), osteopontin (OPN), and the semi-quantitative parameters of 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in lung cancer patients with bone metastasis.

Material and methods: The evaluation included 42 non-small cell lung cancer (NSCLC) and 31 small cell lung cancer (SCLC) patients who were referred to our institution for staging by (18)F-FDG PET/CT. The biochemical parameters measured included CEA and OPN serum levels.

Results: Serum levels of OPN in NSCLC patients with and without bone metastasis were 21.20±4.97 ng/ml and 13.33±4.53 ng/ml, respectively (p<0.05). In SCLC patients with and without bone metastasis serum OPN levels were 23.95±4.78 ng/ml and 17.30±3.09 ng/ml, respectively (p<0.05). Serum levels of CEA in NSCLC patients with and without bone metastasis were 33.79±6.49 ng/ml and 11.74±2.96 ng/ml, respectively (p<0.05). In SCLC patients with and without bone metastasis serum levels of CEA were 28.93±4.59 ng/ml and 13.88±4.47 ng/ml, respectively (p<0.05). There were no correlations between primary tumor SUVmax, and serum levels of CEA and OPN.

Conclusions: Bone metastasis can be detected in patients with lung cancer by measuring CEA and OPN levels. Increased levels of CEA and OPN levels may be considered an early warning sign in patients needing accurate imaging, as they are at higher risk of bone metastasis.

Keywords: Bone metastasis; CEA; Cáncer de pulmón; Lung cancer; Metástasis ósea; OPN; Positron emission tomography; Tomografía de emisión de positrones.

MeSH terms

  • Biomarkers, Tumor / blood
  • Bone Neoplasms / blood*
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary*
  • Carcinoembryonic Antigen / blood*
  • Carcinoma, Non-Small-Cell Lung / blood*
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Humans
  • Lung Neoplasms / blood*
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / pathology
  • Osteopontin / blood*
  • Positron Emission Tomography Computed Tomography*
  • Small Cell Lung Carcinoma / blood*
  • Small Cell Lung Carcinoma / diagnostic imaging
  • Small Cell Lung Carcinoma / secondary

Substances

  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Osteopontin